Jaguar Health, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; comparison is with FY2022. This 10-K does not provide a standalone Q4 income statement or cash-flow summary.
Business context
Jaguar is a commercial-stage pharmaceutical company focused on plant-derived gastrointestinal products. Its principal marketed human product is Mytesi (crofelemer), approved for noninfectious diarrhea in adults with HIV/AIDS receiving antiretroviral therapy. Canalevia-CA1 is conditionally FDA-approved for chemotherapy-induced diarrhea in dogs. The company’s lead human pipeline program is crofelemer for prevention of cancer therapy-related diarrhea (OnTarget, Phase 3); other programs include rare-disease crofelemer formulations and NP-300 for infectious diarrhea.
Key financial metrics
| Metric | FY2023 / Dec. 31, 2023 | FY2022 / Dec. 31, 2022 |
|---|---|---|
| Net product revenue | $9.8 million | $12.0 million |
| Cost of product revenue | $2.0 million | $2.0 million |
| Gross profit and approximate gross margin | $7.7 million; 79% | $9.9 million; 83% |
| Research and development expense | $18.6 million | $17.6 million |
| Sales and marketing expense | $6.5 million | $8.8 million |
| General and administrative expense | $16.6 million | $17.9 million |
| Operating loss | $34.3 million | $34.4 million |
| Net loss | $41.9 million | $48.4 million |
| Net loss attributable to common stockholders | $41.3 million; $1.79 per share | $47.5 million; $36.18 per share |
| Cash used in operating activities | $33.2 million | $33.1 million |
| Cash and cash equivalents | $6.5 million | $5.5 million |
| Total assets / total liabilities | $50.8 million / $45.9 million | $47.5 million / $48.8 million |
| Notes payable, net of discount | $35.9 million | $33.6 million |
| Stockholders’ equity (deficit) | $4.9 million | $(1.4) million |
Gross margin figures are approximate calculations from reported net product revenue less cost of product revenue. FY2023 revenue was heavily concentrated in Mytesi; two customers accounted for 84% of revenue (28% and 56%).
Changes versus FY2022
- Net product revenue declined 18.4%, from $12.0 million to $9.8 million. Mytesi revenue fell from $14.8 million to $13.4 million on a gross-sales basis; net Mytesi revenue was $9.6 million versus $11.7 million. Canalevia and Neonorm revenue remained small.
- Operating expenses decreased 5.0% to $44.1 million. R&D increased 5.4%, while sales and marketing fell 26.9% and G&A fell 7.2%.
- Net loss narrowed to $41.9 million from $48.4 million. Lower interest expense and a debt-extinguishment gain contributed; these were partly offset by a $5.1 million loss from changes in fair value of financial instruments.
- Operating cash use remained broadly flat. Financing activities provided $34.2 million, principally from $32.1 million of net ATM proceeds. The company issued 54.3 million shares through the ATM during 2023, and the outstanding voting share count rose to 73.4 million at year-end from 2.2 million, reflecting financing and other share issuances as well as the prior reverse split.
Liquidity, debt and going concern
- Management and the auditor state there is substantial doubt about the company’s ability to continue as a going concern. The filing says existing cash is not sufficient to fund the operating plan through one year from issuance of the financial statements; additional financing or other funding is needed. The audited statements include no adjustments for the outcome of this uncertainty.
- Cash was $6.5 million at year-end, against $33.2 million of operating cash use in FY2023. The company reports an accumulated deficit of $308.2 million and expects further losses and negative cash flows.
- Net notes payable were $35.9 million, including $30.9 million of notes measured at fair value. The filing reports $5.9 million of contractual note maturities in 2024, before unamortized discounts and costs; payment timing may vary with future revenue.
- Separate from the maturity table, the risk factors cite minimum royalty payments of approximately $14.6 million in 2024, $19.5 million in 2025 and $5.3 million in 2026. These obligations may strain cash resources even if product sales are insufficient.
- Streeterville holds a first-priority security interest in Napo’s NP-300 assets and related collateral. The filing warns that default could permit foreclosure.
Outlook, commentary and material risks
- Management’s stated priorities include Mytesi commercialization, OnTarget Phase 3 development, and crofelemer programs for short bowel syndrome and microvillus inclusion disease. The filing describes planned 2024 studies and the possibility of European early patient access in 2025, subject to study results, regulatory pathways and funding. The near-term clinical milestones are funding-dependent; the filing does not provide a clear quantified revenue or earnings forecast.
- OnTarget was initiated in 2020 and remained a pivotal Phase 3 program; the pipeline table lists unblinding as an anticipated milestone. The supplied filing text does not report trial results.
- Canalevia-CA1 remains conditionally approved, with continued marketing dependent on annual renewals and eventual evidence supporting full approval. Lower-than-anticipated Canalevia and Neonorm sales prompted a $371,000 impairment of internal-use registry software.
- Key risks include the need for substantial additional capital; dependence on Mytesi and two major customers; continued losses; dilution from equity financing; debt and minimum royalty obligations; clinical and regulatory uncertainty; reimbursement and market-acceptance risks; reliance on a limited supplier and contract-manufacturing base; and Nasdaq listing compliance. The company reported a May 2023 minimum-bid-price deficiency and a further grace period through May 6, 2024.
- Material post-year-end financing and dilution: from January 1 through April 1, 2024, the company issued 133.6 million ATM shares for $11.6 million net proceeds. The filing also describes subsequent preferred-stock conversions, warrant exchanges and other share issuances. The cover page reports 276.2 million voting shares outstanding as of April 1, 2024.
- The auditor issued an unmodified opinion on the financial statements, while highlighting going-concern doubt. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not attest to internal control. The company reported no material legal proceedings.
Important facts for investors to verify
- Current cash runway, cash burn and the status, terms and dilution impact of financing raised after year-end.
- The amount, timing and enforceability of minimum royalty payments and other debt obligations, including the fair-value notes and secured NP-300 note.
- Current OnTarget Phase 3 status, unblinding timing and results, and the funding and enrollment status of planned rare-disease studies.
- Mytesi net sales, customer concentration, reimbursement trends and the drivers of the FY2023 revenue decline.
- Canalevia-CA1 renewal and full-approval requirements, sales trajectory, and any subsequent impairment or commercial-supply developments.
- Share count and potential dilution after the numerous 2024 ATM sales, conversions and warrant exchanges; reconcile these with the filing’s reported April 1, 2024 share count.
- Nasdaq listing status after the May 6, 2024 grace-period deadline and any subsequent compliance notices or corporate actions.